ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0128

Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck

Rosachiara Forcignanò1, Fiorella Anna Lombardi2, Mariangela Ciccarese3, Eugenio Quarta4, Antonella Grimaldi5, Laura Quarta5, Delia Ciardo2, Ernesto Casciaro2, Paola Pisani2, Francesco Conversano2, Maurizio Muratore5 and Sergio Casciaro2, 1O.U. of Oncology, “Sacro Cuore di Gesù” Hospital, Gallipoli, Lecce, Italy, Gallipoli, Italy, 2National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, 3O.U. of Oncology, “Vito Fazzi” Hospital, ASL-LE, Lecce, Italy, Lecce, Italy, 4O.U. of Rheumatology, "Galateo" Hospital, ASL-LE, San Cesario di Lecce, Lecce, Italy, San Cesario di Lecce, Italy, 5O.U. of Rheumatology, “Galateo” Hospital, San Cesario di Lecce ASL-LE, Lecce, Italy, San Cesario di Lecce, Italy

Meeting: ACR Convergence 2020

Keywords: , , , ,

Session Information

Date: Friday, November 6, 2020

Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The aim of the study was to carry out a short-term monitoring of the effect of aromatase inhibitors (AI) and Denosumab on bone health in post-menopausal women with breast cancer (BC) with positive estrogen receptor through a bone densitometry performed with Radiofrequency Echographic Multi-Spectrometry (REMS) and Dual-Energy X-ray Absorptiometry (DXA).

Methods: A group of patients (Group A) received AI adjuvant therapy annually and 60 mg Denosumab every 6 months. The other group (Group B) received annual AI therapy only. All patients underwent a femoral neck scan with REMS and DXA before receiving the first AI therapy (T0) and 12 months after (T1). Only REMS scans were repeated after additional 6 months (T2).

The results were analyzed in terms of relative changes in bone mineral density (BMD) compared to the basal value obtained at T0. The analysis of the results was carried out by balancing the two groups by age.

Results: The results of 200 patients were analyzed. As expected, for Group A (assuming Denosumab) an increasing trend in BMD was observed, whereas a decreasing trend in BMD was found for Group B both with REMS and DXA.

The difference between REMS and DXA obtained for patients in each group at each time point was not statistically significant. Instead, the difference between Group A and Group B is statistically significant for DXA (at T1) and REMS (at T1 and T2).

Conclusion: The effect of Denosumab in reducing the risk of fracture in BC patients treated with AIs is well known. The densitometric techniques currently available are not able to monitor BMD in the short term, since the minimum time between two consecutive measurements is at least 1 year [1]. REMS technology, on the other hand, has demonstrated high performance in terms of precision and repeatability of BMD measurement, and the consequent low least significant change (LSC) value [2]: consequently, it might overcome the limit of current densitometric techniques, allowing a repeated exam at 6 months. The results of this study demonstrate the feasibility of short-term follow-up using REMS technology with femoral neck scans.

Disclosure: R. Forcignanò, None; F. Lombardi, None; M. Ciccarese, None; E. Quarta, None; A. Grimaldi, None; L. Quarta, None; D. Ciardo, None; E. Casciaro, None; P. Pisani, None; F. Conversano, None; M. Muratore, None; S. Casciaro, None.

To cite this abstract in AMA style:

Forcignanò R, Lombardi F, Ciccarese M, Quarta E, Grimaldi A, Quarta L, Ciardo D, Casciaro E, Pisani P, Conversano F, Muratore M, Casciaro S. Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/short-term-monitoring-of-denosumab-effect-in-breast-cancer-patients-receiving-aromatase-inhibitors-using-radiofrequency-echographic-multi-spectrometry-rems-technology-on-femoral-neck/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/short-term-monitoring-of-denosumab-effect-in-breast-cancer-patients-receiving-aromatase-inhibitors-using-radiofrequency-echographic-multi-spectrometry-rems-technology-on-femoral-neck/